Mallinckrodt and Endo have entered into a definitive agreement to combine in a $6.7 billion deal, after the companies emerged from bankruptcy in connection...
Ono Pharmaceutical has entered into a license agreement with Ionis Pharmaceuticals for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV).
Sapablursen...